Keros Therapeutics Q2 EPS $(1.25) Misses $(1.23) Estimate, Sales $37.00K
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics (NASDAQ:KROS) reported Q2 earnings per share (EPS) of $(1.25), missing the analyst consensus estimate of $(1.23) by 1.63%. This represents a slight improvement from the $(1.27) per share loss in the same period last year. The company also reported $37.00 thousand in sales for the quarter.
August 07, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Keros Therapeutics reported a Q2 EPS of $(1.25), missing the consensus estimate of $(1.23). Sales were $37.00K. Despite the miss, the loss per share improved slightly from last year.
The EPS miss, although slight, is likely to have a negative short-term impact on the stock price. The improvement from last year's loss is a positive sign but may not be enough to offset the negative sentiment from missing estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100